Cytokinetics, Incorporated, Health Economics and Outcomes Research, South San Francisco, California.
Cytokinetics, Incorporated, Health Economics and Outcomes Research, South San Francisco, California.
Am J Cardiol. 2022 Jul 1;174:120-125. doi: 10.1016/j.amjcard.2022.03.023. Epub 2022 Apr 23.
The clinical profile of patients with obstructive hypertrophic cardiomyopathy (oHC) is not well characterized, with little evidence outside selected referral populations. Using longitudinal medical claims data from a United States nationwide database, we retrospectively identified adults who were newly diagnosed with oHC. Clinical characteristics were compared from 1 year before diagnosis and at the 2-year follow-up. Patients (N = 1,841) with oHC (age 63 ± 15 years; 52% were male) with geographic representation across the United States were identified. Most patients received care within community-based cardiovascular practices and 7% at referral hypertrophic cardiomyopathy (HC) centers. Baseline diagnostic procedures included electrocardiogram (66%), echocardiogram (51%), magnetic resonance imaging (4%), and HC genetic testing (0.7%). Baseline co-morbidities were hypertension (59%), coronary artery disease (30%), diabetes (19%), and atrial fibrillation (19%). For all HC-related medications, use significantly increased after diagnosis. During follow-up, 144 patients (8%) received an implantable cardioverter-defibrillator for sudden death prevention, 99 underwent septal myectomy (5%), and 24 underwent alcohol septal ablation (1%). By the 1-year follow-up, 2% of patients had sudden cardiac arrest and 26% had atrial fibrillation, and heart failure increased from 16% to 27%. In conclusion, in a community-based population of patients with oHC, patients' age at diagnosis of oHC was older than reported for referral populations and patients had a significant co-morbidity burden. Cardiovascular medication use was appropriate, but the rate of guideline-supported surgical procedures was low.
患有梗阻性肥厚型心肌病 (oHC) 的患者的临床特征尚未得到很好的描述,除了在选定的转诊人群之外,几乎没有其他证据。我们使用来自美国全国性数据库的纵向医疗索赔数据,回顾性地确定了新诊断为 oHC 的成年人。比较了从诊断前 1 年和 2 年随访时的临床特征。在美国各地具有地理代表性的患者 (N=1841) 患有 oHC(年龄 63 ± 15 岁;52%为男性)。大多数患者在社区为基础的心血管实践中接受治疗,7%在转诊肥厚型心肌病 (HC) 中心接受治疗。基线诊断程序包括心电图 (66%)、超声心动图 (51%)、磁共振成像 (4%) 和 HC 基因检测 (0.7%)。基线合并症包括高血压 (59%)、冠状动脉疾病 (30%)、糖尿病 (19%)和心房颤动 (19%)。所有与 HC 相关的药物在诊断后均显著增加。在随访期间,144 名患者 (8%)因预防猝死而植入了植入式心脏复律除颤器,99 名接受了室间隔心肌切除术 (5%),24 名接受了酒精室间隔消融术 (1%)。到 1 年随访时,有 2%的患者发生了心搏骤停,26%的患者发生了心房颤动,心力衰竭从 16%增加到 27%。总之,在社区为基础的 oHC 患者人群中,患者 oHC 的诊断年龄大于转诊人群报告的年龄,且患者合并症负担较重。心血管药物的使用是恰当的,但指南支持的手术治疗率较低。